Cost-effectiveness of immune checkpoint inhibition in BRAF wild-type advanced melanoma

Keyphrases

• Cost-effectiveness 100%
• Advanced Melanoma 100%
• Ipilimumab 100%
• Immune Checkpoint Inhibitors 100%
• Nivolumab 80%
• Pembrolizumab 40%
• Metastatic Melanoma 30%
• Quality-adjusted Life Years 30%
• Treatment Strategy 20%
• Markov Model 20%
• Dacarbazine 20%
• Incremental Cost-effectiveness Ratio 20%
• Politicians 10%
• Disease Progression 10%
• Adverse Events 10%
• 5-year Survival 10%
• Improved Patient Outcomes 10%
• Carboplatin 10%
• Randomized Controlled Trial 10%
• Estimated Cost 10%
• Novel Agents 10%
• Optimal Treatment 10%
• U.S. Food 10%
• Initial Treatment 10%
• Randomized Phase III Trial 10%
• Model Uncertainty 10%
• Paclitaxel Chemotherapy 10%
• Treatment Sequence 10%
• Payer Perspective 10%
• Treatment-naïve 10%
• Drug Discontinuation 10%
• State of Health 10%
• Every 2 weeks 10%

Medicine and Dentistry

• Health Care Cost 100%
• Melanoma 100%
• Nivolumab 100%
• Pembrolizumab 62%
• Metastatic Melanoma 37%
• Quality Adjusted Life Year 37%
• Dacarbazine 25%
• Adverse Event 12%
• Survival Rate 12%
• Health Status 12%
• Relative Survival 12%
• Randomized Controlled Trial 12%
• Carboplatin 12%
• Paclitaxel 12%
• Disease Exacerbation 12%
• Lifespan 12%
• Immune Checkpoint Inhibitor 12%
• Chemotherapy 12%
• Phase III Trials 12%

Pharmacology, Toxicology and Pharmaceutical Science

• Melanoma 100%
• Nivolumab 100%
• Pembrolizumab 62%
• Metastatic Melanoma 37%
• Dacarbazine 25%
• Disease Exacerbation 12%
• Adverse Event 12%
• Survival Rate 12%
• Carboplatin 12%
• Paclitaxel 12%
• Randomized Controlled Trial 12%
• Chemotherapy Regimens 12%
• Health Status 12%
• Immune Checkpoint Inhibitor 12%
• Phase III Trials 12%